casirivimab and imdevimab (Ronapreve, REGN-COV2) - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.61 [0.41, 0.92]< 10%1 study (1/-)99.1 %some concernnot evaluable moderatecrucial-
deaths 0.61 [0.41, 0.92]< 10%1 study (1/-)99.1 %some concernnot evaluable moderatecrucial-
death or ventilation 0.66 [0.46, 0.94]< 10%1 study (1/-)98.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.48 [1.05, 2.09]> 10%1 study (1/-)98.6 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.